# SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis

> **NCT02696941** · PHASE1 · COMPLETED · sponsor: **University of Oxford** · enrollment: 20 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Metformin
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT02696941
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2018-04-01
- **Final completion:** 2018-04-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02696941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02696941, "SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02696941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*